Tranilast (N-3,4-dimethoxycinnamoyl anthranilic acid) is an antiallergic agent with inhibitory effects on cell proliferation and extracellular matrix production. Here we assess the effect of tranilast on the expression of miR-29c and genes functionally involved in cell proliferation, fibrosis, and epigenetic regulation in isolated leiomyoma smooth muscle cells (LSMC). Tranilast significantly inhibited the rate of LSMC proliferation, which was associated with downregulation of cell cycle progression genes cyclin D1 (CCND1) and cyclin-dependent kinase 2 (CDK2) expression at messenger RNA and protein levels (P < .05). Tranilast also suppressed the expression of collagen type I (COL1), collagen type III alpha 1 chain (COL3A1), the profibrotic cytokine, transforming growth factor β-3 (TGF-β3), DNA (cytosine-5)-methyltransferase 1 (DNMT1), and enhancer of zeste homolog 2 (EZH2), which regulate epigenetic status of gene promoters (P < .05). Tranilast also significantly induced the expression of cellular and secreted miR-29c through downregulation of methylation status of miR-29c promoter (P < .05). In addition, tranilast suppressed the activity of luciferase reporter containing 3′UTR of COL3A1 and CDK2, which are downstream targets of miR-29c (P < .05). Knockdown of miR-29c expression attenuated the inhibitory effects of tranilast on COL3A1 and CDK2 protein expression (P < .05). Collectively, these findings suggest that tranilast could have therapeutic potential as an inhibitory agent for leiomyoma growth and its associated symptoms.
SegarsJHParrottECNagelJD. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum Reprod Update. 2014;20(3):309–333.
2.
IslamMSProticOStortoniP. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013;100(1):178–193.
3.
LuoXPanQLiuLCheginiN. Genomic and proteomic profiling II: comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars. Reprod Biol Endocrinol. 2007;5:35.
4.
CheginiN. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28(3):180–203.
5.
LeeBSNowakRA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab. 2001;86(2):913–920.
6.
BeheraMAFengLYonishBCatherinoWJungSHLeppertP. Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci (Thousand Oaks, Calif). 2007;14(suppl 8):63–76.
7.
LuoXCheginiN. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med. 2008;26(6):500–514.
8.
De LeoVMorganteGLa MarcaA. A benefit–risk assessment of medical treatment for uterine leiomyomas. Drug Safety. 2002;25(11):759–779.
9.
GrudzienMMLowPSManningPCArredondoMBeltonRJJrNowakRA. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril. 2010;93(4):1290–1298.
10.
BraktaSDiamondJSAl-HendyADiamondMPHalderSK. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015;104(3):698–706.
11.
RogosnitzkyMDanksRKardashE. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res. 2012;32(7):2471–2478.
12.
DarakhshanSPourAB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015;91:15–28.
13.
ShimeHKariyaMOriiA. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53. J Clin Endocrinol Metab. 2002;87(12):5610–5617.
14.
IslamMSProticOCiavattiniA. Tranilast, an orally active antiallergic compound, inhibits extracellular matrix production in human uterine leiomyoma and myometrial cells. Fertil Steril. 2014;102(2):597–606.
15.
ChuangTDKhorramO. Mechanisms underlying aberrant expression of miR-29c in uterine leiomyoma. Fertil Steril. 2016;105(1):236–245.e1.
16.
BannisterAJKouzaridesT. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–395.
17.
SatoFTsuchiyaSMeltzerSJShimizuK. MicroRNAs and epigenetics. FEBS J. 2011;278(10):1598–1609.
18.
BirdA. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6–21.
19.
ChangCJHungMC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243–247.
20.
YangQMasADiamondMPAl-HendyA.The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci. 2016;23(2):163–175.
21.
MaekawaRSatoSYamagataY. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PloS One. 2013;8(6):e66632.
22.
GreathouseKLBredfeldtTEverittJI. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res. 2012;10(4):546–557.
23.
NavarroAYinPMonsivaisD. Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma. PLoS One. 2012;7(3):e33284.
24.
JonesPABaylinSB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–428.
25.
ChuangTDPandaHLuoXCheginiN. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr Relat Cancer. 2012;19(4):541–556.
26.
ChuangTDLuoXPandaHCheginiN. miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8. Mol Endocrinol. 2012;26(6):1028–1042.
27.
ChuangTDHoMKhorramO. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line. Reprod Sci. 2015;22(5):563–571.
28.
ChuangTDKhorramO. miR-200c regulates IL8 expression by targeting IKBKB: a potential mediator of inflammation in leiomyoma pathogenesis. PloS One. 2014;9(4):e95370.
29.
ChuangTDPearceWJKhorramO. miR-29c induction contributes to downregulation of vascular extracellular matrix proteins by glucocorticoids. Am J Physiol Cell Physiol. 2015;309(2):C117–C125.
30.
LiLCDahiyaR. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–1431.
31.
NorianJMMalikMParkerCY. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153–1164.
32.
Prud’hommeGJGlinkaYToulinaAAceOSubramaniamVJothyS. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One. 2010;5(11):e13831.
33.
JinUHKimSBSafeS. Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015;28(5):907–918.
34.
SuwaSKasubataAKatoM. The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies. Int J Oncol. 2015;46(3):1369–1376.
35.
ImbarTGallianoDPellicerALauferN. Introduction: microRNAs in human reproduction: small molecules with crucial regulatory roles. Fertil Steril. 2014;101(6):1514–1515.
36.
PoliEZhangJNwachukwuC. Molecular subtype-specific expression of microRNA-29c in breast cancer is associated with CpG dinucleotide methylation of the promoter. PLOS ONE. 2015;10(11):e0142224.
37.
HuntzingerEIzaurraldeE. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110.
38.
SchickelRBoyerinasBParkSMPeterME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27(45):5959–5974.
39.
PengYLaserJShiG. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008;6(4):663–673.
40.
QiangWLiuZSernaVA. Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma. Endocrinology. 2014;155(3):663–669.
41.
FitzgeraldJBChennathukuzhiVKoohestaniFNowakRAChristensonLK. Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas. Fertil Steril. 2012;98(3):726–734.e2.
MatsuoMNakadaCTsukamotoY. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013;12:15.
44.
SenguptaSden BoonJAChenIH. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A. 2008;105(15):5874–5878.
45.
WangCMWangYFanCG. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011;411(3):586–592.
46.
XiaoLRaoJNZouT. miR-29b represses intestinal mucosal growth by inhibiting translation of cyclin-dependent kinase 2. Mol Biol Cell. 2013;24(19):3038–3046.
47.
LiSChiangTCRichard-DavisGBarrettJCMcLachlanJA. DNA hypomethylation and imbalanced expression of DNA methyltransferases (DNMT1, 3A, and 3B) in human uterine leiomyoma. Gynecol Oncol. 2003;90(1):123–130.
48.
YamagataYMaekawaRAsadaH. Aberrant DNA methylation status in human uterine leiomyoma. Mol Hum Reprod. 2009;15(4):259–267.
49.
DebGThakurVSGuptaS. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013;8(5):464–476.
50.
LiuYLiuTBaoXHeMLiLYangX. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis. Int J Gynecol Pathol. 2014;33(3):218–224.
51.
MooreHMGonzalezMEToyKACimino-MathewsAArganiPKleerCG. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat. 2013;138(3):741–752.
